Kevin Dennis Green Sells 31,148 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 31,148 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $1.50, for a total transaction of $46,722.00. Following the sale, the chief financial officer now directly owns 935,754 shares in the company, valued at $1,403,631. The trade was a 3.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Dennis Green also recently made the following trade(s):

• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Price Performance

Cerus stock opened at $1.48 on Thursday. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The company’s fifty day moving average price is $1.73 and its 200 day moving average price is $1.78. The stock has a market capitalization of $274.97 million, a P/E ratio of -13.45 and a beta of 1.56.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The company had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.81 million. As a group, equities research analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cerus

Several institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Rockport Wealth LLC acquired a new stake in Cerus during the 4th quarter worth $25,000. Cibc World Markets Corp acquired a new stake in Cerus during the 4th quarter worth $26,000. R Squared Ltd purchased a new position in shares of Cerus during the 4th quarter worth $29,000. Virtu Financial LLC purchased a new position in shares of Cerus during the 4th quarter worth $33,000. Finally, Dark Forest Capital Management LP purchased a new position in shares of Cerus during the 4th quarter worth $34,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.